This new report by Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the European skin replacements and substitutes and active wound repair modulators market. Major topics covered by this report include an overview of the healthcare markets of France, Germany, Italy, Spain, and the United Kingdom; an overview of clinical issues in wound management; skin replacement and substitutes including allografts, autografts, xenografts, amniotic membranes, and autologous and tissue-engineered skin replacements and substitutes (e.g., epidermal, dermal, and composite bilayer skin equivalents); and active wound repair modulators including topical antimicrobials, growth factors, gene therapy agents, antibiotics/anti-infectives, hormones, matrix metalloproteinase enzyme inhibitors, neuropeptides, and stem cells.
EXECUTIVE SUMMARY i. Clinical Issues in Wound Management ii. Skin Replacements and Substitutes a. Allografts b. Autografts c. Xenografts d. Amniotic Membranes e. Skin Equivalents f. Skin Replacements and Substitutes, Market Analysis iii. Active Wound Repair Modulators a. Topical Antimicrobial Products b. Growth Factors c. Other Active Wound Repair Modulators d. Active Wound Repair Modulators, Market Analysis iv. Combined Market Analysis a. Market Drivers b. Market Limiters c. Combined Market Forecast Exhibit ES-1: Europe, Skin Replacements and Substitutes, Market Forecast, by Country, 2008-2013 Exhibit ES-2: Europe, Active Wound Repair Modulators, Market Forecast, by Country, 2008-2013 Exhibit ES-3: Europe, Skin Replacements and Substitutes and Active Wound Repair Modulators, Combined Market Forecast, by Country, 2008-2013 1. EUROPEAN HEALTHCARE MARKETS 1.1 The European Union 1.1.1 A Common Currency 1.1.2 Regulatory Policies 1.1.3 Reimbursement 1.1.4 Healthcare Spending 1.2 Selected European National Healthcare Profiles 1.2.1 France 220.127.116.11 Healthcare Organization and Reform 18.104.22.168 Hospital Services 22.214.171.124 Medical Device Reimbursement 1.2.2 Germany 126.96.36.199 Healthcare Organization and Reform 188.8.131.52 Hospital Services 184.108.40.206 Medical Device Reimbursement 1.2.3 Italy 220.127.116.11 Healthcare Organization and Reform 18.104.22.168 Hospital Services 22.214.171.124 Medical Device Reimbursement 1.2.4 Spain 126.96.36.199 Healthcare Organization and Reform 188.8.131.52 Hospital Services 184.108.40.206 Medical Device Reimbursement 1.2.5 United Kingdom 220.127.116.11 Healthcare Organization and Reform 18.104.22.168 Hospital Services 22.214.171.124 Medical Device Reimbursement Exhibit 1-1: European Union, Medical Devices Risk Classification System Exhibit 1-2: European Union Population Statistics Comparison for the Years 1999, 2009, and 2019 Exhibit 1-3: France, Selected National Healthcare Statistics Exhibit 1-4: Germany, Selected National Healthcare Statistics Exhibit 1-5: Italy, Selected National Healthcare Statistics Exhibit 1-6: Spain, Selected National Healthcare Statistics Exhibit 1-7: United Kingdom, Selected National Healthcare Statistics 2. CLINICAL ISSUES IN WOUND MANAGEMENT 2.1 Physiology of Wound Closure 2.1.1 Layers of the Skin and Supporting Structures 126.96.36.199 Epidermis 188.8.131.52 Dermis 184.108.40.206 Subcutaneous Tissue 220.127.116.11 Fascia 18.104.22.168 Muscle 22.214.171.124 Bone 2.1.2 Wound Closure Process 126.96.36.199 Hemostasis 188.8.131.52 Inflammation 184.108.40.206 Proliferation 220.127.116.11 Remodeling Phase 2.2 Factors Affecting Wound Closure 2.2.1 Extrinsic Factors 18.104.22.168 Desiccation 22.214.171.124 Hydration 126.96.36.199 Infection 188.8.131.52 Maceration 184.108.40.206 Medication and Other Treatment Modalities 220.127.116.11 Necrotic Tissue and Debris 18.104.22.168 Oxygenation 22.214.171.124 Stress 126.96.36.199 Temperature 188.8.131.52 Wound Creation and Depth 184.108.40.206 Wound Closure Techniques 220.127.116.11 Other Extrinsic Factors 2.2.2 Intrinsic Factors 18.104.22.168 Body Build 22.214.171.124 Chronic Illness and Age 126.96.36.199 Nutrition 2.2.3 Complications of Wound Healing 188.8.131.52 Bleeding 184.108.40.206 Scarring 2.3 Major Wound Types 2.3.1 Amputation 2.3.2 Arterial Ulcers 2.3.3 Burns 2.3.4 Diabetic Ulcers 2.3.5 Pressure Ulcers 2.3.6 Surgical Wounds 2.3.7 Traumatic Wounds 2.3.8 Venous Ulcers Exhibit 2-1: The Skin's Layers and Supporting Structures Exhibit 2-2: Phases of the Wound Closure Process Exhibit 2-3: Extrinsic and Intrinsic Factors Affecting Wound Closure Exhibit 2-4: Major Wound Types, by Cause Exhibit 2-5: Stages of Burn Wounds Exhibit 2-6: Stages of Pressure Ulcers Exhibit 2-7: 2008, Europe, Surgical Procedure Volumes, by Type 3. SKIN REPLACEMENTS AND SUBSTITUTES MARKET 3.1 Allografts 3.2 Autografts 3.3 Xenografts 3.4 Amniotic Membranes 3.5 Autologous and Tissue-Engineered Skin Replacements and Substitutes 3.5.1 Epidermal Equivalents 3.5.2 Dermal Equivalents 3.5.3 Composite Bilayer Skin Equivalents 3.6 Skin Substitute Products under Development 3.6.1 Advanced BioHealing 3.6.2 Healthpoint/DFB Pharmaceuticals 3.6.3 Organogenesis 3.6.4 Dr. Suwelack Skin & Health Care 3.7 Market Analysis 3.8 Competitive Analysis Exhibit 3-1: Advantages and Disadvantages of Allografts Exhibit 3-2: 2010, Selected Epidermal Equivalent Skin Substitutes Exhibit 3-3: 2010, Selected Dermal Equivalent Skin Substitutes Exhibit 3-4: 2010, Selected Composite Bilayer Equivalent Skin Substitutes Exhibit 3-5: Europe, Skin Replacements and Substitutes, Market Forecast, by Country, 2008-2013 Exhibit 3-6: 2009, Europe, Skin Replacements and Substitutes Market, Share by Supplier 4. ACTIVE WOUND REPAIR MODULATORS MARKET 4.1 Topical Antimicrobials 4.1.1 Products 4.1.2 Market Analysis 4.1.3 Competitive Analysis 4.2 Growth Factors 4.2.1 Classification of Growth Factors 220.127.116.11 Fibroblast Growth Factors 18.104.22.168 Transforming Growth Factors 22.214.171.124 Epidermal Growth Factors 126.96.36.199 Platelet-Derived Growth Factors 188.8.131.52 Insulin-Like Growth Factors 184.108.40.206 Keratinocyte Growth Factors 220.127.116.11 Vascular Endothelial Growth Factors 18.104.22.168 Autologous Growth Factors 22.214.171.124.1 Arteriocyte Medical Systems 126.96.36.199.2 Cytomedix 188.8.131.52.3 Harvest Technologies 184.108.40.206 Angiogenic Growth Factors 4.2.2 Products 4.2.3 Market Analysis 4.3 Gene Therapy Agents 4.4 Other Active Wound Repair Modulators 4.4.1 Antibiotics and Anti-Infectives 220.127.116.11 Basilea Pharmaceutica 18.104.22.168 Cerexa/Forest Laboratories 22.214.171.124 Cubist Pharmaceuticals 126.96.36.199 Helix BioMedix 188.8.131.52 Theravance 4.4.2 Hormones 4.4.3 Matrix Metalloproteinase Enzyme Inhibitors 184.108.40.206 Dermagenics/Greystone Pharmaceuticals 220.127.116.11 Smith & Nephew 18.104.22.168 Systagenix Wound Management 4.4.4 Neuropeptides in Diabetic Wounds 4.4.5 Stem Cells 4.4.6 Other Products 22.214.171.124 Kingfisher Healthcare 126.96.36.199 Pioneer Surgical Orthobiologics/Pioneer Surgical Technology 188.8.131.52 RegeneRx Biopharmaceuticals Exhibit 4-1: 2010, Selected Topical Antimicrobial Products Exhibit 4-2: Europe, Topical Antimicrobial Products, Market Forecast, by Country, 2008-2013 Exhibit 4-3: 2009, Europe, Topical Antimicrobial Products, Share by Supplier Exhibit 4-4: 2010, Selected Growth Factors in Development for Wound Healing Applications Exhibit 4-5: 2010, Selected Angiogenic Growth Factors Exhibit 4-6: Europe, Growth Factors Used in Wound Healing Applications, Market Forecast, by Country, 2008-2013 5. COMPANY PROFILES 5.1 Advanced BioHealing, Inc. 5.2 Cook Biotech, Inc./Cook Group, Inc. 5.3 Cytomedix, Inc. 5.4 Fidia Advanced Biopolymers SRL/Anika Therapeutics, Inc. 5.5 GlaxoSmithKline PLC 5.6 Integra LifeSciences Corporation 5.7 LEO Pharma AS/LEO Foundation 5.8 sanofi-aventis 5.9 Smith & Nephew PLC 5.10 Systagenix Wound Management LTD APPENDIX: COMPANY LISTING